Connie G Glasgow1, Nilo A Avila2, Jing-Ping Lin3, Mario P Stylianou3, Joel Moss4. 1. Translational Medicine Branch, National Institutes of Health, Bethesda, MD. 2. Diagnostic Radiology Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD. 3. Office of Biostatistics Research, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. 4. Translational Medicine Branch, National Institutes of Health, Bethesda, MD. Electronic address: mossj@nhlbi.nih.gov.
Abstract
BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder affecting primarily women of child-bearing age, and characterized by cystic lung destruction, tumors of the kidney (angiomyolipomas [AMLs]), and involvement of the axial lymphatics (lymphangioleiomyomas). Patients with LAM experience loss of pulmonary function attributed to the proliferation of abnormal-appearing smooth muscle-like cells (LAM cells). It is possible to group the LAM population by the presence or absence of extrapulmonary involvement (eg, AMLs, lymphangioleiomyomas, chylous effusions). Serum vascular endothelial growth factor (VEGF)-D, a lymphangiogenic factor, is higher in LAM patients than in healthy volunteers and has been proposed as a tool in the differential diagnosis of cystic lung disease. We assessed serum VEGF-D concentrations in relationship to clinical phenotype in LAM patients. METHODS: Serum VEGF-D levels were quantified by enzyme immunosorbent assay for 111 patients with LAM and 40 healthy volunteers. VEGF-D levels in patients with pulmonary LAM, with or without extrapulmonary manifestations, were compared to those of healthy volunteers. RESULTS: Serum VEGF-D levels were greater in patients with LAM compared to those of healthy volunteers (p < 0.001). However, when patient samples were grouped based on the extent of lymphatic extrapulmonary involvement (eg, lymphangioleiomyomas and adenopathy), the statistical difference was maintained only for patients with LAM with lymphatic involvement (p < 0.001), not for those patients whose disease was restricted to the lung. Serum VEGF-D levels are a good biomarker for lymphatic involvement (area under the curve [AUC], 0.845; p < 0.0001), and a fair predictor for LAM disease (AUC, 0.751; p < 0.0001). Serum levels correlated to CT scan grade (p = 0.033). CONCLUSIONS: Serum VEGF-D concentration is a measure of lymphatic involvement in patients with LAM.
BACKGROUND:Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder affecting primarily women of child-bearing age, and characterized by cystic lung destruction, tumors of the kidney (angiomyolipomas [AMLs]), and involvement of the axial lymphatics (lymphangioleiomyomas). Patients with LAM experience loss of pulmonary function attributed to the proliferation of abnormal-appearing smooth muscle-like cells (LAM cells). It is possible to group the LAM population by the presence or absence of extrapulmonary involvement (eg, AMLs, lymphangioleiomyomas, chylous effusions). Serum vascular endothelial growth factor (VEGF)-D, a lymphangiogenic factor, is higher in LAM patients than in healthy volunteers and has been proposed as a tool in the differential diagnosis of cystic lung disease. We assessed serum VEGF-D concentrations in relationship to clinical phenotype in LAM patients. METHODS: Serum VEGF-D levels were quantified by enzyme immunosorbent assay for 111 patients with LAM and 40 healthy volunteers. VEGF-D levels in patients with pulmonary LAM, with or without extrapulmonary manifestations, were compared to those of healthy volunteers. RESULTS: Serum VEGF-D levels were greater in patients with LAM compared to those of healthy volunteers (p < 0.001). However, when patient samples were grouped based on the extent of lymphatic extrapulmonary involvement (eg, lymphangioleiomyomas and adenopathy), the statistical difference was maintained only for patients with LAM with lymphatic involvement (p < 0.001), not for those patients whose disease was restricted to the lung. Serum VEGF-D levels are a good biomarker for lymphatic involvement (area under the curve [AUC], 0.845; p < 0.0001), and a fair predictor for LAM disease (AUC, 0.751; p < 0.0001). Serum levels correlated to CT scan grade (p = 0.033). CONCLUSIONS: Serum VEGF-D concentration is a measure of lymphatic involvement in patients with LAM.
Authors: D N Franz; A Brody; C Meyer; J Leonard; G Chuck; S Dabora; G Sethuraman; T V Colby; D J Kwiatkowski; F X McCormack Journal: Am J Respir Crit Care Med Date: 2001-08-15 Impact factor: 21.405
Authors: Denise M Crooks; Gustavo Pacheco-Rodriguez; Rosamma M DeCastro; J Philip McCoy; Ji-an Wang; Fumiyuki Kumaki; Thomas Darling; Joel Moss Journal: Proc Natl Acad Sci U S A Date: 2004-12-06 Impact factor: 11.205
Authors: K Matsui; A Tatsuguchi; J Valencia; Z x Yu; J Bechtle; M B Beasley; N Avila; W D Travis; J Moss; V J Ferrans Journal: Hum Pathol Date: 2000-10 Impact factor: 3.466
Authors: Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss Journal: Am J Respir Cell Mol Biol Date: 2018-06 Impact factor: 6.914
Authors: Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Thomas Shawker; Connie G Glasgow; Mario Stylianou; Joel Moss Journal: Chest Date: 2015-10 Impact factor: 9.410
Authors: Lisa R Young; Rhonda Vandyke; Peter M Gulleman; Yoshikazu Inoue; Kevin K Brown; Laura S Schmidt; W Marston Linehan; Fuad Hajjar; Brent W Kinder; Bruce C Trapnell; John J Bissler; David N Franz; Francis X McCormack Journal: Chest Date: 2010-04-09 Impact factor: 9.410
Authors: Elena N Atochina-Vasserman; Elena Abramova; Melane L James; Ryan Rue; Amy Y Liu; Nathan Tessema Ersumo; Chang-Jiang Guo; Andrew J Gow; Vera P Krymskaya Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-10-02 Impact factor: 5.464
Authors: Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Mario Stylianou; Joel Moss Journal: Chest Date: 2017-05-19 Impact factor: 9.410
Authors: Elena A Goncharova; Dmitry A Goncharov; Melane Fehrenbach; Irene Khavin; Blerina Ducka; Okio Hino; Thomas V Colby; Mervyn J Merrilees; Angela Haczku; Steven M Albelda; Vera P Krymskaya Journal: Sci Transl Med Date: 2012-10-03 Impact factor: 17.956
Authors: Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss Journal: Am J Respir Crit Care Med Date: 2016-09-15 Impact factor: 21.405